Alnylam Pharma (ALNY) Tops Q1 EPS by 35c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $239.56 -2.42%
Revenue Growth %: +15.3%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +15.3%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.49), $0.35 better than the analyst estimate of ($1.84). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $243.02 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- UBS cuts KOSPI target by nearly 10% to reflect higher rates
- Lumentum shares rise on analyst upgrades, AI demand outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
